Home >> Research Area >>Natural Products>>Diterpenoids>> 14-Deoxy-11,12-didehydroandrographolide

14-Deoxy-11,12-didehydroandrographolide

CAS# 42895-58-9

14-Deoxy-11,12-didehydroandrographolide

Catalog No. BCN1441----Order now to get a substantial discount!

Product Name & Size Price Stock
14-Deoxy-11,12-didehydroandrographolide: 5mg $207 In Stock
14-Deoxy-11,12-didehydroandrographolide: 10mg Please Inquire In Stock
14-Deoxy-11,12-didehydroandrographolide: 20mg Please Inquire Please Inquire
14-Deoxy-11,12-didehydroandrographolide: 50mg Please Inquire Please Inquire
14-Deoxy-11,12-didehydroandrographolide: 100mg Please Inquire Please Inquire
14-Deoxy-11,12-didehydroandrographolide: 200mg Please Inquire Please Inquire
14-Deoxy-11,12-didehydroandrographolide: 500mg Please Inquire Please Inquire
14-Deoxy-11,12-didehydroandrographolide: 1000mg Please Inquire Please Inquire

Quality Control of 14-Deoxy-11,12-didehydroandrographolide

Number of papers citing our products

Chemical structure

14-Deoxy-11,12-didehydroandrographolide

3D structure

Chemical Properties of 14-Deoxy-11,12-didehydroandrographolide

Cas No. 42895-58-9 SDF Download SDF
PubChem ID 5708351 Appearance White powder
Formula C20H28O4 M.Wt 332.4
Type of Compound Diterpenoids Storage Desiccate at -20°C
Synonyms 14-dehydro Andrographolide; AP10
Solubility DMF : 100 mg/mL (300.82 mM; Need ultrasonic)
Chemical Name 4-[(E)-2-[(1R,4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethenyl]-2H-furan-5-one
SMILES CC12CCC(C(C1CCC(=C)C2C=CC3=CCOC3=O)(C)CO)O
Standard InChIKey XMJAJFVLHDIEHF-CRBRZBHVSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 14-Deoxy-11,12-didehydroandrographolide

The herbs of Andrographis paniculata (Burm. f.) Nees

Biological Activity of 14-Deoxy-11,12-didehydroandrographolide

Description14-Deoxy-11,12-didehydroandrographolide has hypotensive, anti-inflammatory, anti-asthma, and anti-cancer actions, it causes negative chronotropic action and antagonised isoproterenol-induced positive chronotropic actions in a non-competitive and dose-dependent manner. 14-Deoxy-11,12-didehydroandrographolide can effectively ameliorate astrocytic pro-inflammatory reactions and prevent PC12 cell death with different efficacies, it may be candidates for treatment of spinal-cord injury and neurodegeneration.
TargetsCaspase | TNF-α | IL Receptor | ROS | NF-kB | p65 | Adrenergic Receptor
In vitro

14-Deoxy-11,12-didehydroandrographolide inhibits proliferation and induces GSH-dependent cell death of human promonocytic leukemic cells.[Pubmed: 24458985]

J Nat Med. 2014 Apr;68(2):387-94.

14-Deoxy-11,12-didehydroandrographolide (AND2), an analogue of andrographolide, showed more potent cytotoxicity against human promonocytic leukemia (THP-1) cells than adherent cancer cell lines.
METHODS AND RESULTS:
In this study 14-Deoxy-11,12-didehydroandrographolide was isolated from the plant Andrographis paniculata and it was characterized. The antiproliferative effect of 14-Deoxy-11,12-didehydroandrographolide on both adherent (PC-3 and MDAMB) and non-adherent (THP-1 and Jurkat) cancer cell lines was evaluated by MTT assay. The effect of intracellular reduced glutathione (GSH) on 14-Deoxy-11,12-didehydroandrographolide-induced cytotoxicity was studied by conducting cell viability assays on GSH-pretreated cells. The effect of 14-Deoxy-11,12-didehydroandrographolide on the redox status of THP-1 cells was determined by analyzing the endogenous reduced GSH content. Apoptosis induction was confirmed by DNA laddering assay and Western blot analysis using anti-caspase-3 protein antibody. 14-Deoxy-11,12-didehydroandrographolide showed antiproliferative action on both THP-1 and Jurkat cancer cell lines with low IC50 values. Cytotoxicity of AND2 was reversed by GSH pretreatment. AND2 treatment decreased the GSH content by 19.76 % (p < 0.001) in the THP-1 cancer cell line and reduced the cell clumping between the THP-1 cells. Expression of procaspase-3 varied in THP-1 cells during the time course of 14-Deoxy-11,12-didehydroandrographolide treatment. Procaspase-3 expression reached a maximum in treated cells at 32 h and was markedly reduced at 48 h but no procaspase-3 cleavage was observed. The obtained results suggest that 14-Deoxy-11,12-didehydroandrographolide is more effective against leukemia cells. 14-Deoxy-11,12-didehydroandrographolide induced a redox-mediated cell death in THP-1 cells.
CONCLUSIONS:
As 14-Deoxy-11,12-didehydroandrographolide temporarily increased the procaspase-3 expression during treatment, this study encourages the preclinical testing of 14-Deoxy-11,12-didehydroandrographolide against promonocytic leukemia cells in combination with small molecules that directly activate procaspase-3 to caspase-3.

Effects of andrographolide and 14-deoxy-11,12-didehydroandrographolide on cultured primary astrocytes and PC12 cells.[Pubmed: 22154981]

Life Sci. 2012 Feb 13;90(7-8):257-66.

To test the effects of andrographolide (AP1) and 14-Deoxy-11,12-didehydroandrographolide (AP2) on pheochromocytoma cell line 12 (PC12) cells in an astrocyte-rich environment.
METHODS AND RESULTS:
The abilities of AP1 and 14-Deoxy-11,12-didehydroandrographolide to reduce the secretion of pro-inflammatory cytokines Interleukin (IL)-1, IL-6, and Tumor necrosis factor (TNF)-α from stimulated astrocytes were tested. In addition, the abilities of AP1 and 14-Deoxy-11,12-didehydroandrographolide to reduce oxidative stress in astrocytes were tested using an oxidative-sensitive fluorescent dye. The reduction of chondroitin sulfate proteoglycan (CSPG) in stimulated astrocytes was tested using the dot blot method. Reduction of H(2)O(2)-induced death was tested in PC12 cells. Astrocyte-conditioned medium (ACM) and TNF-α-stimulated astrocyte-conditioned medium (SACM) were used to assess the effects of 14-Deoxy-11,12-didehydroandrographolide on PC12 cells treated with H(2)O(2). AP1 and 14-Deoxy-11,12-didehydroandrographolide reduced pro-inflammatory cytokines, reactive oxygen species (ROS), and CSPG in TNF-α stimulated astrocytes. AP1 protected H(2)O(2)-treated PC12 cells cultured in ACM. Co-incubation of PC12 cells in H(2)O(2), and ACM collected from AP1 treated astrocytes did not prevent cell death.
CONCLUSIONS:
AP1 and 14-Deoxy-11,12-didehydroandrographolide effectively ameliorated astrocytic pro-inflammatory reactions and prevented PC12 cell death with different efficacies. These compounds may be candidates for treatment of spinal-cord injury and neurodegeneration.

In vivo

Cardiovascular activity of 14-deoxy-11,12-didehydroandrographolide in the anaesthetised rat and isolated right atria.[Pubmed: 9990649 ]

Pharmacol Res. 1998 Dec;38(6):413-7.


METHODS AND RESULTS:
The cardiovascular activity of 14-Deoxy-11,12-didehydroandrographolide (DDA) from Andrographis paniculata (Burm.f.) Nees (Acanthaceae) was elucidated in anaesthetised Sprague-Dawley (SD) rats and isolated rat right atria. In anaesthetised rats, DDA produced significant falls in mean arterial blood pressure (MAP) and heart rate in a dose-dependent manner with the maximum decrease of 37.6 +/- 2.6% and 18.1 +/- 4.8%, respectively. The ED50 value for MAP was 3.43 mmol kg-1. Pharmacological antagonist studies were done using this dose. The hypotensive action of DDA was not mediated through effects on the alpha-adrenoceptor, muscarinic cholinergic and histaminergic receptors, for it was not affected by phentolamine, atropine as well as pyrilamine and cimetidine. However, it seems to work via adrenoceptors, autonomic ganglia receptor and angiotensin-converting enzyme, since the hypotensive effect of DDA was negated or attenuated in the presence of propranolol, hexamethonium and captopril. In the isolated right atria, DDA caused negative chronotropic action and antagonised isoproterenol-induced positive chronotropic actions in a non-competitive and dose-dependent manner.
CONCLUSIONS:
These results further supported the bradycardia-inducing and beta-adrenoceptor antagonistic properties of DDA in vivo.

Protocol of 14-Deoxy-11,12-didehydroandrographolide

Kinase Assay

Identification of genes involved in the regulation of 14-deoxy-11,12-didehydroandrographolide-induced toxicity in T-47D mammary cells.[Pubmed: 22101062]

Food Chem Toxicol. 2012 Feb;50(2):431-44.

14-Deoxy-11,12-didehydroandrographolide is one of the principle compounds of the medicinal plant, Andrographis paniculata Nees.
METHODS AND RESULTS:
This study explored the mechanisms of 14-Deoxy-11,12-didehydroandrographolide-induced toxicity and non-apoptotic cell death in T-47D breast carcinoma cells. Gene expression analysis revealed that 14-Deoxy-11,12-didehydroandrographolide exerted its cytotoxic effects by regulating genes that inhibit the cell cycle or promote cell cycle arrest. This compound regulated genes that are known to reduce/inhibit cell proliferation, induce growth arrest and suppress cell growth. The growth suppression activities of this compound were demonstrated by a downregulation of several genes normally found to be over-expressed in cancers. Microscopic analysis revealed positive monodansylcadaverine (MDC) staining at 8h, indicating possible autophagosomes. TEM analysis revealed that the treated cells were highly vacuolated, thereby suggesting that 14-Deoxy-11,12-didehydroandrographolide may cause autophagic morphology in these cells.
CONCLUSIONS:
This morphology may be correlated with the concurrent expression of genes known to affect lysosomal activity, ion transport, protein degradation and vesicle transport. Interestingly, some apoptotic-like bodies were found, and these bodies contained multiple large vacuoles, suggesting that this compound is capable of eliciting a combination of apoptotic and autophagic-like morphological characteristics.

Cell Research

Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue of andrographolide, in allergic airway inflammation.[Pubmed: 21598983]

J Nat Prod. 2011 Jun 24;74(6):1484-90.

Our group recently reported novel anti-inflammatory effects of andrographolide (2), a bioactive molecule isolated from Andrographis paniculata, in a mouse asthma model. However, 2 has been shown to possess cytotoxic activity. 14-Deoxy-11,12-didehydroandrographolide (1) is an analogue of 2 that can be isolated from A. paniculata.
METHODS AND RESULTS:
We hypothesized that 14-Deoxy-11,12-didehydroandrographolide retains the anti-inflammatory effects for asthma but is devoid of cytotoxicity. In contrast to 2, 14-Deoxy-11,12-didehydroandrographolide did not elicit any cytotoxic activity in A549 and BEAS-2B human lung epithelial cells and rat basophilic leukemia (RBL)-2H3 cells using a MTS assay. Compound 14-Deoxy-11,12-didehydroandrographolide dose-dependently inhibited ovalbumin (OVA)-induced increases in total and eosinophil counts, IL-4, IL-5, and IL-13 levels in lavage fluid, and serum OVA-specific IgE level in a mouse asthma model. 14-Deoxy-11,12-didehydroandrographolide attenuated OVA-induced airway eosinophilia, mucus production, mast cell degranulation, pro-inflammatory biomarker expression in lung tissues, and airway hyper-responsiveness. This substance also blocked p65 nuclear translocation and DNA-binding activity in the OVA-challenged lung and in TNF-α-stimulated human lung epithelial cells.
CONCLUSIONS:
The present findings reveal for the first time that 14-Deoxy-11,12-didehydroandrographolide retains the anti-inflammatory activities of 2 for asthma probably through the inhibition of NF-κB. 14-Deoxy-11,12-didehydroandrographolide (1) may be considered as a safer analogue of 2 for the potential treatment of asthma.

14-Deoxy-11,12-didehydroandrographolide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

14-Deoxy-11,12-didehydroandrographolide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 14-Deoxy-11,12-didehydroandrographolide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.0084 mL 15.0421 mL 30.0842 mL 60.1685 mL 75.2106 mL
5 mM 0.6017 mL 3.0084 mL 6.0168 mL 12.0337 mL 15.0421 mL
10 mM 0.3008 mL 1.5042 mL 3.0084 mL 6.0168 mL 7.5211 mL
50 mM 0.0602 mL 0.3008 mL 0.6017 mL 1.2034 mL 1.5042 mL
100 mM 0.0301 mL 0.1504 mL 0.3008 mL 0.6017 mL 0.7521 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on 14-Deoxy-11,12-didehydroandrographolide

14-Deoxy-11,12-didehydroandrographolide is an analogue of Andrographolide that can be isolated from A. paniculata. 14-Deoxy-11,12-didehydroandrographolide inhibits NF-κB activation.

In Vitro:14-deoxy-11,12-didehydroandrographolide, a naturally occurring noncytotoxic analogue of Andrographolide, effectively reduces Ovalbumin (OVA)-induced inflammatory cell recruitment into bronchoalveolar lavage (BAL) fluid, IL-4, IL-5, IL-13, and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion, mast cell degranulation, and airway hyper-responsiveness (AHR) in a mouse asthma model, probably via inhibition of NF-κB activity[1].

In Vivo:14-deoxy-11,12-didehydroandrographolide (1 mg/kg) dramatically reduces resistance (Rl) and restores Cdyn in OVA-challenged mice in response to methacholine[1].

References:
[1]. Guan SP, et al. Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue ofandrographolide, in allergic airway inflammation. J Nat Prod. 2011 Jun 24;74(6):1484-90.

Featured Products
New Products
 

References on 14-Deoxy-11,12-didehydroandrographolide

14-Deoxy-11,12-didehydroandrographolide inhibits proliferation and induces GSH-dependent cell death of human promonocytic leukemic cells.[Pubmed:24458985]

J Nat Med. 2014 Apr;68(2):387-94.

14-Deoxy-11,12-didehydroandrographolide (AND2), an analogue of andrographolide, showed more potent cytotoxicity against human promonocytic leukemia (THP-1) cells than adherent cancer cell lines. In this study AND2 was isolated from the plant Andrographis paniculata and it was characterized. The antiproliferative effect of AND2 on both adherent (PC-3 and MDAMB) and non-adherent (THP-1 and Jurkat) cancer cell lines was evaluated by MTT assay. The effect of intracellular reduced glutathione (GSH) on AND2-induced cytotoxicity was studied by conducting cell viability assays on GSH-pretreated cells. The effect of AND2 on the redox status of THP-1 cells was determined by analyzing the endogenous reduced GSH content. Apoptosis induction was confirmed by DNA laddering assay and Western blot analysis using anti-caspase-3 protein antibody. AND2 showed antiproliferative action on both THP-1 and Jurkat cancer cell lines with low IC50 values. Cytotoxicity of AND2 was reversed by GSH pretreatment. AND2 treatment decreased the GSH content by 19.76 % (p < 0.001) in the THP-1 cancer cell line and reduced the cell clumping between the THP-1 cells. Expression of procaspase-3 varied in THP-1 cells during the time course of AND2 treatment. Procaspase-3 expression reached a maximum in treated cells at 32 h and was markedly reduced at 48 h but no procaspase-3 cleavage was observed. The obtained results suggest that AND2 is more effective against leukemia cells. AND2 induced a redox-mediated cell death in THP-1 cells. As AND2 temporarily increased the procaspase-3 expression during treatment, this study encourages the preclinical testing of AND2 against promonocytic leukemia cells in combination with small molecules that directly activate procaspase-3 to caspase-3.

Cardiovascular activity of 14-deoxy-11,12-didehydroandrographolide in the anaesthetised rat and isolated right atria.[Pubmed:9990649]

Pharmacol Res. 1998 Dec;38(6):413-7.

The cardiovascular activity of 14-Deoxy-11,12-didehydroandrographolide (DDA) from Andrographis paniculata (Burm.f.) Nees (Acanthaceae) was elucidated in anaesthetised Sprague-Dawley (SD) rats and isolated rat right atria. In anaesthetised rats, DDA produced significant falls in mean arterial blood pressure (MAP) and heart rate in a dose-dependent manner with the maximum decrease of 37.6 +/- 2.6% and 18.1 +/- 4.8%, respectively. The ED50 value for MAP was 3.43 mmol kg-1. Pharmacological antagonist studies were done using this dose. The hypotensive action of DDA was not mediated through effects on the alpha-adrenoceptor, muscarinic cholinergic and histaminergic receptors, for it was not affected by phentolamine, atropine as well as pyrilamine and cimetidine. However, it seems to work via adrenoceptors, autonomic ganglia receptor and angiotensin-converting enzyme, since the hypotensive effect of DDA was negated or attenuated in the presence of propranolol, hexamethonium and captopril. In the isolated right atria, DDA caused negative chronotropic action and antagonised isoproterenol-induced positive chronotropic actions in a non-competitive and dose-dependent manner. These results further supported the bradycardia-inducing and beta-adrenoceptor antagonistic properties of DDA in vivo.

Identification of genes involved in the regulation of 14-deoxy-11,12-didehydroandrographolide-induced toxicity in T-47D mammary cells.[Pubmed:22101062]

Food Chem Toxicol. 2012 Feb;50(2):431-44.

14-Deoxy-11,12-didehydroandrographolide is one of the principle compounds of the medicinal plant, Andrographis paniculata Nees. This study explored the mechanisms of 14-Deoxy-11,12-didehydroandrographolide-induced toxicity and non-apoptotic cell death in T-47D breast carcinoma cells. Gene expression analysis revealed that 14-Deoxy-11,12-didehydroandrographolide exerted its cytotoxic effects by regulating genes that inhibit the cell cycle or promote cell cycle arrest. This compound regulated genes that are known to reduce/inhibit cell proliferation, induce growth arrest and suppress cell growth. The growth suppression activities of this compound were demonstrated by a downregulation of several genes normally found to be over-expressed in cancers. Microscopic analysis revealed positive monodansylcadaverine (MDC) staining at 8h, indicating possible autophagosomes. TEM analysis revealed that the treated cells were highly vacuolated, thereby suggesting that 14-Deoxy-11,12-didehydroandrographolide may cause autophagic morphology in these cells. This morphology may be correlated with the concurrent expression of genes known to affect lysosomal activity, ion transport, protein degradation and vesicle transport. Interestingly, some apoptotic-like bodies were found, and these bodies contained multiple large vacuoles, suggesting that this compound is capable of eliciting a combination of apoptotic and autophagic-like morphological characteristics.

Effects of andrographolide and 14-deoxy-11,12-didehydroandrographolide on cultured primary astrocytes and PC12 cells.[Pubmed:22154981]

Life Sci. 2012 Feb 13;90(7-8):257-66.

AIMS: To test the effects of andrographolide (AP1) and 14-Deoxy-11,12-didehydroandrographolide (AP2) on pheochromocytoma cell line 12 (PC12) cells in an astrocyte-rich environment. MAIN METHODS: The abilities of AP1 and AP2 to reduce the secretion of pro-inflammatory cytokines Interleukin (IL)-1, IL-6, and Tumor necrosis factor (TNF)-alpha from stimulated astrocytes were tested. In addition, the abilities of AP1 and AP2 to reduce oxidative stress in astrocytes were tested using an oxidative-sensitive fluorescent dye. The reduction of chondroitin sulfate proteoglycan (CSPG) in stimulated astrocytes was tested using the dot blot method. Reduction of H(2)O(2)-induced death was tested in PC12 cells. Astrocyte-conditioned medium (ACM) and TNF-alpha-stimulated astrocyte-conditioned medium (SACM) were used to assess the effects of AP2 on PC12 cells treated with H(2)O(2). KEY FINDINGS: AP1 and AP2 reduced pro-inflammatory cytokines, reactive oxygen species (ROS), and CSPG in TNF-alpha stimulated astrocytes. AP1 protected H(2)O(2)-treated PC12 cells cultured in ACM. Co-incubation of PC12 cells in H(2)O(2), and ACM collected from AP1 treated astrocytes did not prevent cell death. SIGNIFICANCE: AP1 and AP2 effectively ameliorated astrocytic pro-inflammatory reactions and prevented PC12 cell death with different efficacies. These compounds may be candidates for treatment of spinal-cord injury and neurodegeneration.

Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue of andrographolide, in allergic airway inflammation.[Pubmed:21598983]

J Nat Prod. 2011 Jun 24;74(6):1484-90.

Our group recently reported novel anti-inflammatory effects of andrographolide (2), a bioactive molecule isolated from Andrographis paniculata, in a mouse asthma model. However, 2 has been shown to possess cytotoxic activity. 14-Deoxy-11,12-didehydroandrographolide (1) is an analogue of 2 that can be isolated from A. paniculata. We hypothesized that 1 retains the anti-inflammatory effects for asthma but is devoid of cytotoxicity. In contrast to 2, 1 did not elicit any cytotoxic activity in A549 and BEAS-2B human lung epithelial cells and rat basophilic leukemia (RBL)-2H3 cells using a MTS assay. Compound 1 dose-dependently inhibited ovalbumin (OVA)-induced increases in total and eosinophil counts, IL-4, IL-5, and IL-13 levels in lavage fluid, and serum OVA-specific IgE level in a mouse asthma model. Compound 1 attenuated OVA-induced airway eosinophilia, mucus production, mast cell degranulation, pro-inflammatory biomarker expression in lung tissues, and airway hyper-responsiveness. This substance also blocked p65 nuclear translocation and DNA-binding activity in the OVA-challenged lung and in TNF-alpha-stimulated human lung epithelial cells. The present findings reveal for the first time that 1 retains the anti-inflammatory activities of 2 for asthma probably through the inhibition of NF-kappaB. 14-Deoxy-11,12-didehydroandrographolide (1) may be considered as a safer analogue of 2 for the potential treatment of asthma.

Description

14-Deoxy-11,12-didehydroandrographolide is an analogue of Andrographolide that can be isolated from A. paniculata. 14-Deoxy-11,12-didehydroandrographolide inhibits NF-κB activation.

Keywords:

14-Deoxy-11,12-didehydroandrographolide,42895-58-9,14-dehydro Andrographolide; AP10,Natural Products, buy 14-Deoxy-11,12-didehydroandrographolide , 14-Deoxy-11,12-didehydroandrographolide supplier , purchase 14-Deoxy-11,12-didehydroandrographolide , 14-Deoxy-11,12-didehydroandrographolide cost , 14-Deoxy-11,12-didehydroandrographolide manufacturer , order 14-Deoxy-11,12-didehydroandrographolide , high purity 14-Deoxy-11,12-didehydroandrographolide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: